1. Executive Summary
2. North America Cervical Cancer Test (Screening) Analysis
2.1 North America Cervical Cancer Test Population
2.1.1 Pap Smear Test Population
2.1.2 HPV DNA Test Population
2.2 North America Cervical Cancer Test (Screening) Market
2.2.1 Pap Smear Test Market
2.2.2 HPV DNA Test Market
3. Market & Population Share – By Countries
3.1 Population Share – By Countries
3.1.1 Pap Smear Population
3.1.2 HPV DNA Population
3.2 Market Share – By Countries
3.2.1 Pap Smear Test Market
3.2.2 HPV DNA Test Market
4. United States – Cervical Cancer Test Analysis
4.1 Population – Cervical Cancer Test (Screening)
4.1.1 Pap smear Test Population
4.1.2 HPV DNA Test Population
4.2 United States Cervical Cancer Mortality
4.3 Market – Cervical Cancer Test (Screening)
4.3.1 Pap Smear Test Market
4.3.2 HPV DNA Test Market
5. Canada – Cervical Cancer Test Analysis
5.1 Population – Cervical Cancer Test (Screening)
5.1.1 Pap Smear Test Population
5.1.2 HPV DNA Test Population
5.2 Canada Cervical Cancer Mortality
5.3 Market – Cervical Cancer Test (Screening)
5.3.1 Pap Smear Test Market
5.3.2 HPV DNA Test Market
6. Growth Drivers
6.1 High Prevalence of HPV Infected Patients
6.2 Worldwide Rising Incidence of Teenage Sexual Cases
7. Challenges
7.1 Introduction of HPV Vaccination Programs Worldwide
List of Figures:
Figure 2‑1: North America – Cervical Cancer Test Population (Million), 2011 – 2017
Figure 2‑2: North America – Forecast for Cervical Cancer Test Population (Million), 2018 – 2024
Figure 2‑3: North America – Cervical Cancer Pap smear Test Population (Million), 2011 – 2017
Figure 2‑4: North America – Forecast for Cervical Cancer Pap smear Test Population (Million), 2018 – 2024
Figure 2‑5: North America – Cervical Cancer HPV DNA Test Population (Million), 2011 – 2017
Figure 2‑6: North America – Forecast for Cervical Cancer HPV DNA Test Population (Million), 2018 – 2024
Figure 2‑7: North America – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 2‑8: North America – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 2‑9: North America – Cervical Cancer Pap Smear Test Market (Million US$), 2011 – 2017
Figure 2‑10: North America – Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2018 – 2024
Figure 2‑11: North America – Cervical Cancer HPV DNA Test Market (Million US$), 2011 – 2017
Figure 2‑12: North America – Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2018 – 2024
Figure 3‑1: North America – Cervical Cancer Test Population Share (%), 2011 – 2017
Figure 3‑2: North America – Forecast for Cervical Cancer Test Population Share (%), 2018 – 2024
Figure 3‑3: North America – Cervical Cancer Pap smear Test Population Share (%), 2011 – 2017
Figure 3‑4: North America – Forecast for Cervical Cancer Pap smear Test Population Share (%), 2018 – 2024
Figure 3‑5: North America – Cervical Cancer HPV DNA Test Population Share (%), 2011 – 2017
Figure 3‑6: North America – Forecast for Cervical Cancer HPV DNA Test Population Share (%), 2018 – 2024
Figure 3‑7: North America – Cervical Cancer Test Market Share (%), 2011 – 2017
Figure 3‑8: North America – Forecast for Cervical Cancer Test Market Share (%), 2018 – 2024
Figure 3‑9: North America – Cervical Cancer Pap smear Test Market Share (%), 2011 – 2017
Figure 3‑10: North America – Forecast for Cervical Cancer Pap smear Test Market Share (%), 2018 – 2024
Figure 3‑11: North America – Cervical Cancer HPV DNA Test Market Share (%), 2011 – 2017
Figure 3‑12: North America – Forecast for Cervical Cancer HPV DNA Test Market Share (%), 2018 – 2024
Figure 4‑1: United States – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 4‑2: United States – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 4‑3: United States – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 4‑4: United States – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 4‑5: United States – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 4‑6: United States – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 4‑7: United States – Cervical Cancer Mortality (Number), 2011 – 2017
Figure 4‑8: United States – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 4‑9: United States – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 4‑10: United States – Pap smear Test Market (Million US$), 2011 – 2017
Figure 4‑11: United States – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 4‑12: United States – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 4‑13: United States – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024
Figure 5‑1: Canada – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 5‑2: Canada – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 5‑3: Canada – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 5‑4: Canada – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 5‑5: Canada – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 5‑6: Canada – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 5‑7: Canada – Cervical Cancer Mortality (Number), 2011 – 2017
Figure 5‑8: Canada – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 5‑9: Canada – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 5‑10: Canada – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 5‑11: Canada – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 5‑12: Canada – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 5‑13: Canada – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024
List of Tables:
Table 6‑1: Worldwide – Prevalence of HPV 16/18 in Women with Normal Cervical Cytology (Percent), 2014 - 2015
Table 6‑2: Worldwide – Prevalence (Percent) of Young Women (15–44 Years) who Have Sex before the Age of 15 Years, 1994 – 2006
